1. Stabilization treatment of remitted psychotic depression: the STOP-PD study
- Author
-
Anthony J. Rothschild, Ellen M. Whyte, Benoit H. Mulsant, Amanda Artis, Kathleen Bingham, Barnett S. Meyers, Samprit Banerjee, Alastair J. Flint, and George S. Alexopoulos
- Subjects
Adult ,Blood Glucose ,Male ,Olanzapine ,medicine.medical_specialty ,Psychosis ,Psychotic depression ,Placebo ,Placebos ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Pharmacotherapy ,Double-Blind Method ,Sertraline ,Internal medicine ,medicine ,Humans ,Triglycerides ,Depression (differential diagnoses) ,Aged ,Depressive Disorder, Major ,Cholesterol ,business.industry ,Body Weight ,Remission Induction ,Middle Aged ,medicine.disease ,Antidepressive Agents ,030227 psychiatry ,3. Good health ,Diagnostic and Statistical Manual of Mental Disorders ,Psychiatry and Mental health ,Psychotic Disorders ,chemistry ,Drug Therapy, Combination ,Female ,business ,030217 neurology & neurosurgery ,Antipsychotic Agents ,medicine.drug - Abstract
Objective We conducted a 12-week double-blind study of stabilization pharmacotherapy in patients with remitted psychotic depression (PD). Methods Seventy-one persons aged 18 years or older who had achieved remission of PD when randomized to either olanzapine plus sertraline or olanzapine plus placebo were continued on the double-blind treatment associated with remission. Symptoms of depression and psychosis, and weight, were measured once every 4 weeks. Cholesterol, triglycerides, and glucose were measured at stabilization phase baseline and Week 12/termination. Results The effect of treatment did not significantly change with time for depression, weight, or metabolic measures in the stabilization phase. Eight of the 71 participants (11.3%; 95% CI: 5.8, 20.7) experienced a relapse of major depression, psychosis, or both. Treatment groups did not differ in the frequency of relapse. In the entire study group, the adjusted estimate for change in weight was an increase of 1.66 kg (95% CI: 0.83, 2.48) and the adjusted estimate for change in total cholesterol was a decrease of 14.8 mg/dL (95% CI: 3.5, 26.1) during the 12-week stabilization phase; the remaining metabolic measures did not significantly change. Conclusion Continuation of acute treatment was associated with stability of remission.
- Published
- 2018
- Full Text
- View/download PDF